NPHLA Intelligence
Clinical Trial Watch
Trials NPHLA follows, synchronised from ClinicalTrials.gov. We flag what matters (new registrations, changes in status and newly posted results) and ignore routine record edits. Every therapy in a trial is investigational.
- GINEBRA: Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
Esbjerg Hospital - University Hospital of Southern Denmark. Conditions: Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions. Investigational — not approved for the use studied.
- ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-10-01. Investigational — not approved for the use studied.
- REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Results posted 2023-08-15. Investigational — not approved for the use studied.
- Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
Novo Nordisk A/S. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim. Conditions: Obesity. Investigational — not approved for the use studied.
- Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Zomagen Biosciences Ltd.. Conditions: Obesity. Results posted 2026-09-29. Investigational — not approved for the use studied.
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- TELWA: Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists
Nordic Biotic Sp. z o.o.. Conditions: Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2. Investigational — not approved for the use studied.
- SILENCED: Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
University Hospital, Gentofte, Copenhagen. Conditions: Obesity &Amp; Overweight. Investigational — not approved for the use studied.
- Tirzepatide for Obesity and Meth Use Disorder
University of Texas Southwestern Medical Center. Conditions: Obesity; Methamphetamine Use Disorder. Investigational — not approved for the use studied.
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Novo Nordisk A/S. Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Investigational — not approved for the use studied.
- Body Fat as Determinant of Female Gonadal Dysfunction
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Conditions: Polycystic Ovary Syndrome; Hypothalamic Amenorrhea. Investigational — not approved for the use studied.
- ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-09-15. Investigational — not approved for the use studied.
- ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company. Conditions: OSA; Overweight or Obesity. Investigational — not approved for the use studied.
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy. Investigational — not approved for the use studied.
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma. Conditions: Overweight; Type 2 Diabetes; Obesity. Investigational — not approved for the use studied.
- ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight; Type 2 Diabetes. Results posted 2026-09-04. Investigational — not approved for the use studied.
- ACHIEVE-1: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company. Conditions: Type 2 Diabetes. Results posted 2026-04-22. Investigational — not approved for the use studied.
- This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control
General Committee of Teaching Hospitals and Institutes, Egypt. Conditions: Micronutrient Deficiencies. Investigational — not approved for the use studied.
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Beni-Suef University. Conditions: Polycystic Ovary. Investigational — not approved for the use studied.
- TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Investigational — not approved for the use studied.
- LIGHT-MCI: LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Conditions: Type 2 Diabetes Mellitus; Mild Cognitive Impairment. Investigational — not approved for the use studied.
- TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. Investigational — not approved for the use studied.
- TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company. Conditions: Obesity; Cardiovascular Diseases. Investigational — not approved for the use studied.
- GLP1-AD-TTE: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
West China Hospital. Conditions: Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight. Investigational — not approved for the use studied.
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly and Company. Conditions: Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly and Company. Conditions: Diabetes Type 2. Investigational — not approved for the use studied.
- TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company. Conditions: Obesity; Overweight; Osteo Arthritis Knee. Investigational — not approved for the use studied.
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Investigational — not approved for the use studied.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Trial listings are not recommendations to enrol or prescribe.